Claritas Announces Effective Date for Share Consolidation
July 20, 2021 17:04 ET
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, July 20, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the "Company" or "Claritas") is pleased to announce that the previously...
Claritas Announces Commitments from Company’s Largest Shareholders to Vote for Approval of Share Consolidation
June 10, 2021 07:15 ET
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, June 10, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced that it has...
Claritas Announces Transfer of GVHD Program and Cancellation of Related Debt as Company Focuses on Nitric Oxide Therapeutics
June 01, 2021 07:15 ET
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has...
Claritas Pharmaceuticals Issues Letter to Shareholders
May 11, 2021 08:30 ET
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, May 11, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE (TSXV): CLAS and OTC: KALTF) (the “Company” or “Claritas”) today issued the following...
Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107
April 21, 2021 05:00 ET
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, April 21, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has entered into...
Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH
April 14, 2021 13:51 ET
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, April 14, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that it has entered into...
Claritas to Expand R-107 Program to Include Treatment of Sepsis, the Leading Cause of Death in COVID-19 Patients
April 08, 2021 08:15 ET
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced that, based on...
Kalytera Therapeutics Inc. Completes Name Change to Claritas Pharmaceuticals, Inc.
April 02, 2021 15:00 ET
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, April 02, 2021 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the "Company" or "Kalytera") today announced that the Company has changed...
Claritas Announces Completion of IND-Enabling In Vitro Genotoxicity Studies with R-107
April 01, 2021 08:30 ET
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas")...
Claritas Announces Addition of Perenlei Enkhbaatar, M.D., Ph.D., FAHA to the Company’s Board of Directors
March 26, 2021 08:30 ET
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO and TORONTO, March 26, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas")...